News|Articles|May 1, 2004

Ezetimibe added to statin results in greater achievement of LDL goals

Ezetimibe added to a stable dose of statin therapy reduces low-densitylipoprotein (LDL) cholesterol by an additional 23% and results in significantlymore patients achieving their LDL cholesterol goals, said Thomas Pearson,MD, MPH, at the 53rd Annual Scientific Session of the American College ofCardiology (ACC) in New Orleans.

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Subscribe Now!

Latest CME

Multimedia

Burst CME™: Exploring Diagnosis and Testing Innovations for Targetable Mutations in SCLC

Jacob Sands, MD; Carl M. Gay, MD, PhD

Multimedia

Burst CME™: Addressing Diagnostic Challenges and Identifying Targets for Treatment in LCNEC-L

Jacob Sands, MD; Martin Wermke, MD

Multimedia

Burst CME™: Advanced Diagnostic and Testing Approaches for Mutation-Targetable Management of NSCLC

Jacob Sands, MD; Julia Rotow, MD

Ezetimibe added to statin results in greater achievement of LDL goals

Newsletter

Related Content

Pharmacy leaders in ASHP survey worry about 340B program changes

Transparency paves the way for lower costs and equitable access

New self-injectable biologics promise cost savings and patient convenience

CMS negotiates a 70% discount for Ozempic and Wegovy

FDA approves $2.59 million gene therapy for SMA

Latest CME

Burst CME™: Exploring Diagnosis and Testing Innovations for Targetable Mutations in SCLC

Burst CME™: Addressing Diagnostic Challenges and Identifying Targets for Treatment in LCNEC-L

Burst CME™: Advanced Diagnostic and Testing Approaches for Mutation-Targetable Management of NSCLC

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | Missouri

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | New Mexico

Community Oncology Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer – From Innovation to Practice | North Carolina

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | West Virginia

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Tennessee

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Washington

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | Texas

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Arkansas

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Kentucky

Community Oncology Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer – From Innovation to Practice | New York

Community Oncology Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer – From Innovation to Practice | Iowa

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | Minnesota

Inaugural Brain & Spine Metastases Conference: Evolving Practice and Emerging Therapies

23rd Annual Winter Lung Cancer Conference®

2nd Annual Hawaii Cancer Conference

Burst CME™: The Role of HER2 in NSCLC and Implications for Emerging Treatment Strategies

Community Practice Connections™: 19th Annual New York Lung Cancers Symposium®

Future Directions in Treating SCLC and LCNEC-L: The Impact of DLL3

42nd Annual CFS: Chemotherapy Foundation Symposium®: Innovative Cancer Therapy for Tomorrow

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

Community Practice Connections™: Incorporating Recent Updates in the Treatment of Metastatic ALK-Positive NSCLC

Virtual Testing Board: Digging Deeper on Your Testing Reports to Elevate Patient Outcomes in Advanced Non–Small Cell Lung Cancer

Mastering Advances in Managing Unresectable and Metastatic NSCLC—Immunotherapy, Targeted Therapies, and Emerging Strategies

Cases & Conversations™: Expert Perspectives on Leveraging Recent Advances to Transform SCLC Treatment

22nd Annual Winter Lung Cancer Conference®

Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies

Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies

(CME Credit) Advancing Outcomes in Limited-Stage Small Cell Lung Cancer: From Evidence to Practice

Medical Crossfire®: The Precision Path for HER2 and TROP2-Targeted Treatments in Non–Small Cell Lung Cancer

PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies

Medical Crossfire®: DLL3-Driven Innovations in Small Cell Lung Cancer – How Do Experts Apply Pivotal Advances to Practice?

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

27th Annual International Lung Cancer Congress®

Breaking Down the Latest Clinical Data for First-line Maintenance and R/R SCLC

Practical Considerations and Future Directions for New Treatment Strategies in SCLC

Navigating Treatment Gaps in SCLC: Relapse, Resistance, and Need for New Options

Community Practice Connections™: Distinguishing Precision Pathways for c-Met and MET Alterations in NSCLC

A New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and ADCs

Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum

26th Annual International Lung Cancer Congress

(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

21st Annual New York Lung Cancers Symposium®

Personalized Approaches in NSCLC: Early Detection, Molecular Testing, and Targeted Therapies

9th Annual School of Nursing Oncology™

Community Practice Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages

Community Practice Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer—From Innovation to Practice

20th Annual New York Lung Cancers Symposium®

Cases and Conversations™: Transforming Small Cell Lung Cancer Treatment Through Emerging Evidence and Expert Insights

3rd Annual Hawaii Lung: A Multidisciplinary Case-Based Conference

(Pharmacist Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

Trending on Managed Healthcare Executive

Johns Hopkins experts warn of potentially severe flu season, measles elimination status faces risk

Many PCPs unaware of current ACIP shingles vaccine guidance, study finds

Will the end of enhanced ACA subsidies mean the beginning of a health insurance crisis?

Top 5 most-read stories out of the 2025 AAD annual meeting

Pharmacy leaders in ASHP survey worry about 340B program changes